Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib (Airecon) plus abiraterone acetate and prednisone vs placebo plus abiraterone/prednisone in high-volume metastatic hormone-sensitive prostate cancer
CTR20232861Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in prostate adenocarcinoma, sponsored by Hengrui Therapeutics. Started Nov 2023; status: active.
02
Drugs
dalpiciclib
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on CTR20232861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232861.